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Abstract
Background: Based on epidemiological commonalities, multiple sclerosis (MS) and
Hodgkin lymphoma (HL), two clinically distinct conditions, have long been suspected to
be aetiologically related. MS and HL occur in roughly the same age groups, both are
associated with Epstein-Barr virus infection and ultraviolet (UV) light exposure, and they
cluster mutually in families (though not in individuals). We speculated if in addition to
sharing environmental risk factors, MS and HL were also genetically related. Using data
from genome-wide association studies (GWAS) of 1816HL patients, 9772MS patients
and 25 255 controls, we therefore investigated the genetic overlap between the two
diseases.
Methods: From among a common denominator of 404 K single nucleotide polymorph-
isms (SNPs) studied, we identified SNPs and human leukocyte antigen (HLA) alleles
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independently associated with both diseases. Next, we assessed the cumulative gen-
ome-wide effect of MS-associated SNPs on HL and of HL-associated SNPs on MS. To
provide an interpretational frame of reference, we used data from published GWAS to
create a genetic network of diseases within which we analysed proximity of HL and MS
to autoimmune diseases and haematological and non-haematological malignancies.
Results: SNP analyses revealed genome-wide overlap between HL and MS, most prom-
inently in the HLA region. Polygenic HL risk scores explained 4.44% of HL risk
(Nagelkerke R2), but also 2.36% of MS risk. Conversely, polygenic MS risk scores ex-
plained 8.08% of MS risk and 1.94% of HL risk. In the genetic disease network, HL was
closer to autoimmune diseases than to solid cancers.
Conclusions: HL displays considerable genetic overlap with MS and other autoimmune
diseases.
Introduction
Hodgkin lymphoma (HL) is an immunologically active ma-
lignant neoplasm of B cells in a heterogeneous reactive cellu-
lar infiltrate.1 HL is roughly equally common in men and
women, and in socioeconomically affluent populations HL
occurrence displays a bimodal age distribution, with separ-
ate peaks in younger adults (15-34 years old) and older
adults (over 50 years old).2–4 In socioeconomically deprived
settings, in contrast, there is no young adult HL incidence
peak, but rather one among children.5
Multiple sclerosis (MS) is a debilitating disease of the
central nervous system (CNS) characterized by chronic
polycellular inflammation (including T cells, monocytes
and B cells), myelin loss, gliosis, axonal and oligodendro-
cyte pathology and accumulation of progressive neuro-
logical disability.6 Onset is typically between the ages of
20 to 40 years, with a female to male ratio of three to one.6
Based on conspicuous epidemiological similarities be-
tween the two conditions, e.g. regarding age patterns and
geographical distributions, Newell in 1970 proposed that
HL and MS were somehow aetiologically related.7
Subsequent epidemiological studies have tested this hy-
pothesis by assessing clustering of HL with MS in individ-
uals and in families. Whereas previous studies generally
suggest that patients suffering from either condition are
not at increased risk of the other,8–16 two partially overlap-
ping investigations have reported mutual clustering of the
two diseases among first-degree relatives.17,18
Familial clustering of HL and MS may reflect shared en-
vironmental and genetic risk factors. Evidence implicates
infection with the Epstein-Barr virus (EBV)19–22 and levels
of ultraviolet light exposure23,24 in the pathogenesis of the
roughly one-third of HL cases that harbour EBV in the ma-
lignant cells (EBV-positive HL), as well as in the pathogen-
esis of MS. Moreover, common genetic risk factors have
emerged in HL and MS.25–28 For example, HLA-A*02 ap-
pears to be associated with a decreased risk of both MS29
and EBV-positive HL,30,31 and DNA variants in the Relish
oncogene (REL, a member of the NF-kappaB transcription
factor family) have been associated with both MS32 and
the EBV-negative subset of HL.25 This suggests that the re-
lationship between HL and MS is not limited to either
EBV-positive or EBV-negative HL.
Unveiling of aetiological commonalities for HL and MS
could contribute to the understanding of their pathogenesis
and might even have clinical implications. We therefore
combined data from previous genome-wide association
studies (GWAS) of MS28 and HL26,27,33,34 and evaluated
the genetic overlap between the two diseases.
Methods
Overview
Analysis was performed on a total of 1816 HL patients,
9772 MS patients and 25 255 controls, using 404 K single
Key Messages
• Epidemiological similarities have suggested common aetiologies for Hodgkin lymphoma and multiple sclerosis.
• Consistent with this hypothesis, detailed analyses reveal considerable genetic overlap between Hodgkin lymphoma
and multiple sclerosis.
• Genetically, Hodgkin lymphoma lies closer to autoimmune diseases than to solid cancers.
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nucleotide polymorphisms (Figure 1). We first sought to iden-
tify single nucleotide polymorphisms (SNPs) and HLA alleles
that associated independently with both diseases. Next, we
calculated polygenic risk scores to assess the cumulative gen-
ome-wide effect of MS-associated SNPs on HL, and of HL-
associated SNPs on MS. To describe the overlap between HL
and MS, we performed a protein interaction network-based
pathway analysis (PINBPA) on associated genes from each
disease, and then investigated the intersection of networks for
biological relevance. To place the genetic similarity between
HL and MS in context, we used data from previously re-
ported GWAS to create a diseasome: a network of diseases.
Within the diseasome, we analysed proximity of HL and MS
to autoimmune diseases and haematological and non-haem-
atological malignancies (‘solid’ cancers).
HL and MS dataset characteristics
The HL26,27,33,34 and MS28 cohorts have previously been
described in detail. For MS, data from the Wellcome Trust
Case Control Consortium 2 meta-analysis project totalled
9772 cases and 17 376 controls. Individuals in this dataset
were of European descent and originated from 15 geograph-
ical regions, including the USA, Australia, New Zealand and
numerous European countries. Included in this dataset were
summary-level association results for a total of 464 434 SNPs.
For HL, data from a recent meta-analysis of three
GWAS studies consisted of 1816 cases and 7879 controls.34
Individuals in this dataset were of European descent and ori-
ginated from locations in the USA and Europe. Summary-
level meta-association results were included for a total of 1
036 304 SNPs. The cases were subdivided into nodular
lymphocytic predominant and classical HL, and classical
HL further divided into subgroups by EBV tumour status
(EBV-positive and EBV-negative) as determined by immu-
nohistochemistry or in situ hybridization as previously
described27 and histology [mixed cellularity (MC), nodular
sclerosis (NS) and other or unspecified], when such data
were available. Summary characteristics are shown in Table
S1 (available as Supplementary data at IJE online).
The HL and MS datasets were merged (by rsID), giving a
final dataset containing summary-level results for 404 069
overlapping SNPs.
Overlap between diseases: SNP-level
We followed a procedure similar to that used in other meta-
analyses of complex genetic diseases.35 To assess genetic
Figure 1. Study design and data analysis procedures. Results from previously reported genome-wide associations studies (GWAS) of Hodgkin lymph-
oma (HL) and multiple sclerosis (MS) were used to assess genetic overlap between the two diseases. Single nucleotide polymorphisms (SNPs) inde-
pendently associated with both HL and MS were identified, and disease-specific polygenic risk scores were compared in HL cases, MS cases and
healthy controls. Protein-interaction network-based pathway analysis (PINBPA) was performed on the intersection of nominally associated (P < 0.05)
SNPs in HL and MS and gene ontology (GO) analysis was performed to identify common genetic pathways. Genetic similarity between HL and MS
was further evaluated in the context of other immune diseases, haematological malignancies and solid cancers by constructing a diseasome using
data from previously reported GWAS.
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overlap between HL and MS, we sought SNPs that associated
independently with both diseases. We identified top (P-value
< 5 x 108) independent (r2 < 0.1 in CEU) MS-susceptibility
SNPs, and determined how many of these SNPs are associ-
ated with HL after correction by Benjamini-Hochberg
method (corrected P-value< 0.05). The process was repeated
for increasingly liberal values of the P-value threshold for
defining MS susceptibility SNPs (ranging from P-value < 5 x
108 to P-value < 5 x 102). Corresponding analysis was re-
peated after switching roles for HL and MS. The HLA region
was analysed in further detail using imputed classical HLA al-
leles (see Supplementary methods for details, available as
Supplementary data at IJE online).
Supplementary analysis considered MS SNPs on subsets
of the HL dataset as defined by tumour EBV status (EBV-
positive HL and EBV-negative HL), tumour histology
[nodular sclerosis (NS), mixed cellularity (MC)], or tu-
mour histology combined with age (NS among 15-35 year
olds), in order to explore possible heterogeneity among the
HL samples.
Overlap between diseases: polygenic risk
Polygenic risk scores were calculated to test the cumulative
effect of SNPs associated with HL on MS and vice versa, as
described in detail in other complex genetic diseases.32,35–
37 For each trait (HL and MS), sets of top independent
SNPs were chosen as described above. Multiple sclerosis
genetic burden (MSGB) and Hodgkin lymphoma genetic
burden (HLGB) were calculated for each individual: the
weighted sum of the number of risk alleles at each SNP in
the set, weighted by the log-odds ratio of association for
each SNP. We assessed the ability of MSGB to distinguish
HL cases from controls and the ability of HLGB to distin-
guish MS cases from controls using the Nagelkerke’s R2
(note that the P-values of the linear regression models will
largely be driven by large sample sizes, and the biological
significance lies in the R2 value rather than the P-value).
This analysis was repeated for subgroups of HL (EBV-posi-
tive, EBV-negative, MC and NS).
Protein interaction network-based pathway
analysis (PINBPA)
To visualize the sets of interacting genes found to associate
with both HL and MS, a protein interaction network-
based pathway analysis (PINBPA) was performed using
methods described previously.32 Sub-networks of aggre-
gate score of three or greater were chosen as associated.
Network discovery was performed independently in HL
and MS, networks of score three or greater being chosen as
associated. The intersection of the HL and MS networks
was visualized. Gene ontology analysis was performed on
genes in this intersection.
Diseasome analysis
To further assess genetic similarity between HL and MS, a
representation of the human diseasome (network of dis-
eases)38,39 was constructed in which diseases (nodes) were
connected by the extent of their shared genetic aetiology
(edges)40,41 as reported by the GWAS catalogue42. This
network is termed the diseasome. Diseases were manually
classified as haematological malignancies, solid cancers
or autoimmune diseases. Pairwise proximity measures
between diseases were calculated as described in
Supplementary methods. Relative distances between hae-
matological malignancies, solid cancers, and auto-immune
diseases were tested by t-test.
Results
SNP and HLA allele overlap between HL and MS
We identified SNPs associated with MS across multiple
P-value thresholds ranging from P-value < 5 x 108 to
P-value < 5 x 102. Among these SNPs, we then identified
those that were also associated with HL (FDR < 0.05; false
discovery rate with Benjamini-Hochberg adjustment of
P-values for the total number of SNPs tested at each
threshold) (Table 1).
At a threshold of P-value < 5 x 108, 429 SNPs were
associated with MS; 36 of these 429 were independent (r2
< 0.1), and three of these 36 were associated with HL at
an FDR < 0.05 (Benjamini-Hochberg correction for 36
tests), summarized in row 1 of Table 1. Panel 1 of Table 1
shows results for other P-value thresholds and panel 2
shows results when top HL SNPs were tested for associ-
ation in MS. SNPs found to be overlapping (final column
of Table 1) are described in Table 2 (after HLA is
removed). While the actual number and proportion of
overlapping SNPs varied by the P-value threshold, the ma-
jority of overlapping SNPs belonged to genes in the HLA
region of chromosome 6; however, several mutually associ-
ated non-HLA SNPs were also detected (Table 2; Figure
S1, Table S2, available as Supplementary data at IJE on-
line). It should be noted that the direction of association
was not taken into account in this analysis, which reveals
only shared genetic risk loci (see genetic burden analysis
below, which accounts for direction of association).
The SNP-level overlap between diseases was repeated for
each HL subgroup: MS versus EBV-positive HL, MS versus
EBV-negative HL, MS versus NS-HL, MS versus NS-HL in
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15 to 35-year-olds and MS versus MC-HL. These analyses
revealed no major differences between HL subgroups.
Given the strong genetic overlap at HLA, HLA alleles were
imputed from SNP information via the HIBAG algorithm (see
Supplementary methods, available as Supplementary data at
IJE online). Figure 2 demonstrates overlap between risk alleles
for EBV-negative HL and risk alleles for MS, as well as over-
lap between protective alleles for EBV-negative HL and pro-
tective alleles for MS. In contrast, there is no overlap between
risk alleles for EBV-positive HL and risk alleles for MS,
whereas there is overlap between protective alleles for EBV-
positive HL and protective alleles for MS. Table S3 (available
as Supplementary data at IJE online) provides details of HLA
allelic P-values and odds ratios in each disease. Analysis of
NS-HL revealed a pattern similar to EBV-negative HL.
Polygenic risk overlap between diseases
To assess the extent of genetic risk overlap between HL
and MS at the genome-wide level (including HLA), poly-
genic risk scores, termed MS genetic burden (MSGB) and
HL genetic burden (HLGB) were calculated in all cases of
MS, all cases of HL and all controls used in the MS study.
Figure 3A shows the MSGB (y-axis) in each population. As
expected, the MSGB was higher in MS cases than in con-
trols (P-value < 1.0 x 10200) and explained 8.08% of the
risk for MS (Nagelkerke’s R2). However, the MSGB was
also higher in HL cases than in controls (P-value < 2.8 x
1035) and explained 1.94% of the risk for HL. Figure 3B
shows the HLGB (y-axis) in each population. As expected,
the HLGB was higher in HL cases than in controls (P-value
< 2.8 x 1081) and explained 4.44% of the risk for HL.
However, HLGB was also higher in MS cases compared
with controls (P-value < 2.0 x 10121) and explained
2.36% of the MS risk. Results shown here use a threshold
of P-value < 5 x 106 for including SNPs in the polygenic
risk score, which results in 76 independent SNPs used for
MSGB and 17 independent SNPs used for HLGB. Similar
results held true at other P-value thresholds. We observed
no major differences among HL subgroups.
Pathway analysis
To generate hypotheses about potential functional path-
ways that are common to HL and MS, we carried out
PINBPA in each independent dataset based on the
Table 1.Overlap of associated SNPs in HL and MS at increasing thresholds
Top MS-associated SNPs in HL
MS P-value threshold Number of SNPs associated
with MS
Number of independent
MS SNPs
Number of independent
MS SNPs also associated
with HL (FDR < 0.05)
5 x 1028 429 36 3
5 x 1027 497 50 4
5 x 1026 601 76 6
5 x 1025 825 138 4
5 x 1024 1422 386 3
0.005 4317 1715 3
0.05 24225 9107 2
Top HL-associated SNPs in MS
HL P-value threshold Number of SNPs associated
with HL
Number of independent
HL SNPs
Number of independent
HL SNPs also associated
with MS (FDR < 0.05)
5 x 1028 11 6 5
5 x 1027 23 12 9
5 x 1026 37 17 12
5 x 1025 60 30 15
5 x 1024 291 165 19
0.005 2053 1155 32
0.05 17541 7196 36
In the upper panel, top MS-associated SNPs at a given P-value threshold (column 1) are counted (column 2), thinned to include only independent SNPs (column
3). Independent MS SNPs are tested in HL for association; the number of independent SNPs which pass FDR < 0.05 in HL is shown (column 4). In the lower
panel, the top HL SNPs are counted, thinned and tested for association with MS.
LD, linkage disequilibrium; FDR, Benjamini-Hochberg false discovery rate, adjusted for the total number of independent SNPs tested.
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nominally associated SNPs. We found 100 associated mod-
ules (with threshold of score > 3) in MS comprising 1404
genes and 4050 edges, and 100 associated modules in HL
comprising 1049 genes and 3652 edges. The intersection of
the HL and MS networks yielded a network of 430 genes
and 1066 edges. A gene ontology (GO) analysis of this
intersection network using the software binGO revealed
enrichment in JUN kinase activity, antigen processing and
presentation, peptidyl-tyrosine phosphorylation and
lymphocyte-mediated immunity (Figure 4; Table S4, avail-
able as Supplementary data at IJE online). When the ana-
lysis was repeated after a seven mega-base region
surrounding the HLA was masked, the antigen processing
and presentation pathway was no longer associated but
JUN kinase activity, peptidyl-tyrosine phosphorylation and
lymphocyte-mediated immunity remained.
Diseasome analysis
To assess the relative position of HL and MS among other
autoimmune diseases and cancers (in terms of shared genetic
risk), pairwise proximities were calculated among 37 complex
autoimmune diseases, solid cancers and haematological
malignancies (Table 3), where proximity is a network-based
relatedness measure derived from shared GWAS loci between
diseases. Autoimmune diseases showed more genetic
Table 2. Non-HLA SNPs associated with both HL and MS at decreasing thresholds
Top: a grey box indicates that an SNP was associated with MS (at the P-value threshold shown in the top row), and was also associated with HL (FDR < 0.05;
adjusted for the total number of SNPs that were tested in HL at the given MS threshold). Bottom: a grey box indicates that an SNP was associated with HL (at the
P-value threshold shown in the top row), and was also associated with MS (FDR < 0.05; adjusted for the total number of SNPs that were tested in MS at the given
HL threshold). Only independent SNPs are shown (r2 < 0.1). The HLA region is omitted.
CHR, chromosome.
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similarity to other autoimmune diseases than to solid cancers
(P ¼ 3.5 x 1038, Figure 5A), and analogously, the individual
solid cancers showed more genetic similarity to other solid
cancers than to autoimmune diseases (P ¼ 5.4 x 109, Figure
5C). MS was closer to other autoimmune diseases than to
solid cancers (P¼ 9.2 x 106, Figure 5D).
Haematological malignancies, as a group, displayed ap-
proximately equal proximity to solid cancers and autoim-
mune disorders (P ¼ 0.49 for a difference, Figure 5B).
However, when the haematological malignancies were
considered individually, HL was closer to autoimmune dis-
eases than to solid cancers (P ¼ 0.01, Figure 5E). Chronic
Figure 2. Legend. Classical HLA alleles were imputed in each disease using SNP data. Each point in each plot represents a classical HLA allele. Axes
represent the odds ratio of association for each allele in the designated disease. Protective alleles have odds ratios less than 1 (lower values on each
axis) and risk alleles have odds ratios greater than 1 (high values on each axis). (A) HLA risk alleles for EBV-positive HL tend to be neutral for EBV-
negative HL, while HLA risk alleles for EBV-negative HL are neutral to protective for EBV-positive HL. Some HLA alleles are protective for both dis-
eases. (B) HLA risk alleles for EBV-positive HL are neutral or protective for MS, and HLA risk alleles for MS are neutral or protective for EBV-positive
HL. There are a large number of HLA alleles which are protective for both MS and EBV-positive HL. (C) There is an overlap between HLA risk alleles
for MS and EBV-negative HL, and overlap between protective alleles for MS and EBV-negative HL.
Figure 3. Polygenic risk scores demonstrate overlap between diseases. Hodgkin lymphoma (HL) and multiple sclerosis (MS) polygenic risk scores in
HL cases, MS cases and healthy controls. A. MS genetic burden (MSGB) on y-axis, an aggregate measure of MS genetic risk across the genome of a
given individual (includes human leukocyte antigen region of chromosome 6). MSGB is higher in HL cases than controls, indicating genetic overlap
between HL and MS. B. HL genetic burden (HLGB) on y-axis, an aggregate measure of HL genetic risk across the genome of a given individual (in-
cludes human leukocyte antigen region of chromosome 6). HLGB is higher in MS cases than controls, indicating genetic overlap between HL and MS.
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lymphocytic leukaemia (CLL) was also closer to autoim-
mune diseases (P ¼ 0.038, Figure S2 available as
Supplementary data at IJE online) but also shared some
loci with solid cancers. In contrast, multiple myeloma
(MM) was closer to solid cancers than to autoimmune dis-
eases (P ¼ 0.08, Figure S2). Figure 6 is a graphical repre-
sentation of the proximity network between diseases.
Discussion
In this study, we undertook a series of analyses exploring gen-
etic overlap between HL and MS. We found that top HL-
associated SNPs were associated with MS, and conversely
that top MS-associated SNPs were associated with HL.
Overlap was particularly prominent in the HLA region of
chromosome 6 but also applied to non-HLA loci. Genetic
overlap between HL and MS was also observed in analyses
of disease-specific polygenic risk scores (HLGB and MSGB)
which included the HLA region. The HLGB explained
4.44% of the risk of HL and the MSGB explained 1.94% of
the risk of HL. Similarly, MSGB explained 8.08% of the risk
of MS and HLGB explained 2.36% of the risk for MS. Thus,
the MSGB captured approximately 40% of the genetic sus-
ceptibility to HL measured by the HLGB and the HLGB cap-
tured approximately 30% of the genetic susceptibility to MS
measured by the MSGB. Additionally, pathway analysis sug-
gested shared biological pathways between HL and MS,
involving a common theme of immune activation and cell
proliferation, including lymphocyte-mediated immunity,
positive regulation of JUN kinase activity (which plays roles
in cellular response to stress, T cell differentiation, inflamma-
tion and apoptosis), peptidyl-tyrosine-phosphorylation (a
non-specific intermediate step in multiple tyrosine pathways)
and antigen processing and presentation.
The shared genetic element between HL and MS suggested
by the present investigation is consistent with the original hy-
pothesis of shared associations between the two conditions
and with their previously observed mutual clustering within
Figure 4. Protein-interaction network-based pathway analysis (PINBPA) and gene ontology (GO). Four top pathways identified using GO analysis on
PINBPA networks discovered in both Hodgkin lymphoma (HL) and multiple sclerosis (MS). A. Positive regulation of JUN kinase activity. B. Antigen
processing and presentation of peptide antigen. C. Peptidyl-tyrosine phosphorylation. D. Lymphocyte-mediated immunity. Individual gene P-values
for MS and HL are indicated when P < 0.05 (*) or when P < 0.1 (‡).
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families.17,18 Therefore further investigation of pathogenic
pathways shared by these two clinically distinct conditions,
similar to those being conducted for other neurodegenerative
diseases associated with cancer risk,43 is warranted.
Both EBV-positive and EBV-negative HL44–46 and MS47
have been consistently and strongly associated with HLA al-
leles. Our study confirms that this locus confers the highest
known effect for the three phenotypes. Interestingly, in strati-
fied analyses the patterns of overlap with MS clearly differed
between EBV-positive HL and EBV-negative HL. Risk alleles
were shared between EBV-negative HL and MS, but not be-
tween EBV-positive HL and MS. These findings suggest that
EBV-positive HL and EBV-negative HL may each be inde-
pendently associated with MS, but via different genes.
The precise mechanisms underlying the HLA associations
have not been firmly established either for HL or MS. In MS,
one immune model holds that T cells, activated peripherally
by an infectious agent, cross the blood-brain barrier and in-
duce MS lesions upon reactivation by myelin fragment anti-
gens presented in the context of HLA.48 For HL, speculation
has centred primarily on its presumed infectious aeti-
ology,30,31,44 with EBV present and expressing antigens with
plausible pathogenic functions in all tumour cells and there-
fore likely playing a causative role in the EBV-positive subset
of HL.49 Moreover, like MS,22 EBV-positive HL has been
Figure 5. Diseasome analysis reveals that haematological malignancies
lie somewhere between autoimmune diseases and solid cancer. A.
Proximity of autoimmune diseases to other diseases. Density plots rep-
resent all possible pair-wise proximities between autoimmune diseases
and solid cancers (orange), and all pair-wise proximities between auto-
immune diseases and other autoimmune disease (purple). Higher de-
gree of proximity (higher values on the x-axis) indicates more genetic
similarity to autoimmune diseases. The P-value indicates that autoim-
mune diseases are closer to other autoimmune diseases than to solid
cancers. B. Proximity of haematological malignancies to solid cancers
(orange) and to autoimmune diseases (purple). Haematological malig-
nancies show genetic overlap with both solid cancers and autoimmune
diseases.C. Proximity of solid cancers to other solid cancers (orange)
and to autoimmune diseases (purple).Solid cancers are closer to other
solid cancers than to autoimmune diseases. D. Proximity of MS to all
diseases. Each circle represents a disease in the diseasome. Higher de-
grees of proximity (higher values on x-axis) represent more genetic
similarity with MS. Solid cancers are orange, autoimmune diseases are
purple, HL is white. The P-value indicates MS is closer to autoimmune
diseases than to solid cancers. E. Proximity of HL to all diseases. HL is
closer to autoimmune diseases than to solid cancers.
Table 3. Classification of immune and neoplastic diseases
from the diseasome
Autoimmune diseases Solid cancers
Alopecia areata (AR) Basal cell carcinoma (BCC)
Ankylosing spondylitis (AS) Bladder carcinoma (BLC)
Behcet’s disease (Beh) Breast carcinoma (BRC)
Coeliac disease (Cel) Central nervous system cancer (CNS)
Crohn’s disease (CD) Oesophageal carcinoma (OESC)
Graves’ disease (GD) Lung adenocarcinoma (LUA)
IGa glomerulonephritis (IGA) Lung carcinoma (LUC)
Kawasaki disease (KAW) Melanoma (MEl)
Multiple sclerosis (MS) Ovarian carcinoma (OVC)
Primary biliary cirrhosis (PBC) Pancreatic carcinoma (PAC)
Psoriasis (PS) Prostate carcinoma (PRC)
Psoriatic arthritis (PSA) Renal cell carcinoma (RCC)
Rheumatoid arthritis (RA) Squamous cell carcinoma (SCC)
Sclerosing cholangitis (PSC) Stomach carcinoma (STC)
Systemic lupus erythematosus (SLE) Thyroid carcinoma (THC)
Systemic scleroderma (SS)
Type 1 diabetes mellitus (T1D)
Ulcerative colitis (UC)
Vitiligo (Vit)
Haematological cancers
Chronic lymphocytic leukemia (CLL)
Hodgkin lymphoma (HL)
Multiple myeloma (MM)
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associated with infectious mononucleosis caused by primary
EBV infection20 and with aberrant anti-EBV nuclear antigen
antibody patterns, albeit different from those associated with
MS.19,21 Accordingly, HLA-specific variation in immune re-
sponse to EBV infection may mediate the effects of the HLA
associations shared by EBV-positive HL and MS. Although
an analogous scenario involving an HLA-specific immune re-
sponse directed against an infectious organism different from
EBV may be envisioned for EBV-negative HL, no such agent
has been linked to this HL subgroup50 or to MS as yet.
Construction of a diseasome based on disease-gene associ-
ations42 showed that the close genetic relationship between
HL and the autoimmune disease MS applied to a broad spec-
trum of autoimmune conditions and that HL was in general
closer to autoimmune diseases than to solid cancers.
Importantly, the observation was not entirely explained by
HLA, and the close relationship between HL and autoim-
mune conditions remained when the diseasome analysis was
repeated after masking a seven mega-base region surrounding
the HLA region. In line with this, there is evidence to suggest
that the risk of HL is increased in patients with autoimmune
diseases such as rheumatoid arthritis and systemic lupus ery-
thematosus.51,52 In the absence of evidence of familial cluster-
ing of HL and autoimmune diseases,53 mechanisms such as
chronic immune stimulation and/or immune-modulating
treatment have been considered the most plausible explan-
ations for the association. However, the present analyses sug-
gest that shared genetic constitution may also contribute to
the increased prevalence of HL among patients with autoim-
mune diseases (though an interaction between genetics and
immune-modulating treatment is also a possibility). Indeed,
our approach of combining GWAS data may prove more effi-
cient in demonstrating overlapping pathogenic pathways be-
tween diseases than traditional epidemiological analytical
designs, which may suffer from inadequate statistical power.
Besides HL, the diseasome analysis also included two
other haematological malignancies. Among these, CLL
was also closer to autoimmune diseases whereas multiple
Figure 6. Human disease network shows distinct autoimmune and solid cancer clusters and places hematologic cancers in context. In a network of
disease proximity, constructed using systematic GWAS data, autoimmune diseases (purple) tightly cluster. Solid cancers (orange) also form a distinct
cluster, but exhibit less relatedness in terms of genetic etiology than autoimmune diseases. Hematologic cancers (white) do not form a cohesive clus-
ter and instead ranged from autoimmune related to solid cancer related. Hodgkin lymphoma (HL), in particular, appeared strongly autoimmune. See
table 3 for a list of abbreviations.
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myeloma showed similarity to solid cancers. CLL belongs
to the group of non-Hodgkin lymphomas54 and, although
strong associations between autoimmune disorders and
CLL per se have not been noted,55 an increased risk of the
combined group of non-Hodgkin lymphomas among pa-
tients with various autoimmune diseases is well docu-
mented in the literature.56
The main limitation of the present study was the uneven
distribution of HL and MS patients with GWAS data and
the lack of independent validation datasets. These limita-
tions likely do not affect the diseasome results which are
based on multiple GWAS in each disease and are robust to
the removal of any single GWAS. However, SNP-level
summary data for other autoimmune diseases and other
cancers would have allowed assessment of polygenic risk
scores and specific genetic overlap between other pairs of
diseases that were closely associated in the diseasome, i.e.
in the same way that the genetic overlap between HL and
MS was assessed. Perhaps the diseasome analysis will pro-
vide impetus for further collaborative meta-analyses of
haematologicalmalignancies and autoimmune diseases.
In summary, this study demonstrated commonalities in
the genetic susceptibility to HL and MS as evidenced by
analyses of individual SNPs, polygenic risk scores and pro-
tein-interaction networks. Diseasome analysis further sug-
gested that HL shares a genetic architecture more similar
to that of autoimmune diseases than to solid cancers. We
speculate that autoimmune diseases and HL are different
manifestations of a shared underlying genetic syndrome.
Supplementary Data
Supplementary data are available at IJE online.
Funding
Funding for this project was obtained from the Nordic Cancer
Union (16-02-D to H.H.), the Lundbeck Foundation (R19-A2364 to
H.H.), the Danish Cancer Research Foundation (41-08 to H.H.), the
National Institutes of Health (CA110836 to W.C.; HD0433871,
CA129045, and CA40046 to K.O.; CA55727 to L.L.R.; CA58839
to T.M.M.), the United States Army Medical Research and Materiel
Command (Department of Defense PR054600 to W.C.), the
American Cancer Society Illinois Division (to K.O.), the American
Lebanese Syrian Associated Charities (to L.L.R.), the Leukemia &
Lymphoma Society (TR6137-07 to W.C.), the Cancer Research
Foundation (to K.O.), the National Cancer Institute Surveillance
Epidemiology and End Results Population-based Registry Program
at the National Institutes of Health in the Department of Health and
Human Services (R01-NS-026799 to J.R.O., N01-PC-35139 to
W.C. and N01-PC-35136 to the Cancer Prevention Institute of
California), the National Cancer Institute (263-MQ-417755 to
S.L.G.), the Leukemia Lymphoma Research and Kay Kendall
Leukemia fund (grant 12022 to R.F.J.), the California Cancer
Registry and the Dutch Cancer Society (KWF grants RUG 2009-
4313 and RUG 2014-6698 to A.v.d.B.), the National Science
Foundation (Graduate Research Fellowship Grant 1144247 to
D.S.H.) and the Center for Neuroengineering and Therapeutics at
the University of Pennsylvania (P.K.).
Acknowledgments
We thank the Childhood Cancer Survivor Study (National Cancer
Institute grant U24 CA 55727) for the Hodgkin Lymphoma data,
and the International Multiple Sclerosis Genetics Consortium and
the Wellcome Trust Case-Control Consortium for the multiple scler-
osis data. We would like to thank Hans-Olov Adami, David Conti,
Arjan Diepstra, Bengt Glimelius, Annette Lake, Dorothy
Montgomery, Les Robison, Malcolm Taylor, and Maria Timofeeva
for data accrual, sample handling and analysis of Hodgkin lymph-
oma data. We would like to thank Stacy J. Caillier and Sarah Beth
Hill for assistance with figure creation.
Author contributions
Contributions: P.K., W.C., D.S.H., S.E.B., J.D.M., J.R.O. and H.H.
designed the experiment. P.K., D.S.H., L.M., L.D., T.M., J.M.M.,
A.L., P.A.G., M.D.S., D.L. and J.D.M. analysed the data. A.v d B.,
S.L.G., K.E.S., T.M.M., S.d.S., A.N., S.L.H., P.C., M.M., L.F., A.S.,
M.D.S., S.B., M.M., K.O., R.J., J.D.M., J.R.O. and H.H. contrib-
uted reagents, materials and analysis tools. P.K., W.C., D.S.H.,
S.E.B., P.A.G., R.J., J.D.M., J.R.O. and H.H. wrote the paper. All
authors read and approved the final manuscript.
Conflict of interest: The authors have no conflicts of interest to
disclose.
References
1. Stein H. Hodgkin lymphoma - Introduction. In: Swerdlow SH,
Campo E, Harris NL et al. (eds). Tumours of Haematopoietic
and Lymphoid Tissues. Lyon, France: IARC Press, 2008.
2. MacMahon B. Epidemiology of Hodgkin’s disease. Cancer Res
1966;26:1189–.
3. Mueller N, Grufferman S. Hodgkin lymphoma. In: Schottenfeld
D, Fraumeni JJr (eds). Cancer Epidemiology and Prevention. 3rd
edn. Oxford, UK: Oxford University Press, 2006.
4. MacMahon B. Epidemiological evidence of the nature of
Hodgkin’s disease. Cancer 1957;10:1045–13.
5. Correa P, O’Conor GT. Epidemiologic patterns of Hodgkin’s
disease. Int J Cancer 1971;8:192–201.
6. Hauser S, Goodin DS. Multiple sclerosis and other demyelinat-
ing diseases. In: Longo DL, Fauci AS, Kasper DL, Hauser SL,
Jameson L, Loscalzo J (eds). Harrison’s Principles of Internal
Medicine. 18th edn. New York, NY: McGraw-Hill, 2012.
7. Newell GR. Etiology of multiple sclerosis and Hodgkin’s disease.
Am J Epidemiol 1970;91:11–22.
8. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T.
Cancer risk among patients with multiple sclerosis and their par-
ents. Neurology 2009;72:1170–77.
9. Bernard SM, Cartwright RA, Darwin CM et al. Hodgkin’s dis-
ease: case control epidemiological study in Yorkshire. Br J
Cancer 1987;55:85–90.
10. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying
cause of death in Danish patients with multiple sclerosis: results
International Journal of Epidemiology, 2016, Vol. 0, No. 0 11
 at Periodicals D
ept on M
arch 21, 2016
http://ije.oxfordjournals.org/
D
ow
nloaded from
 
from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg
Psychiatry 1998;65:56–59.
11. Lebrun C, Debouverie M, Vermersch P et al. Cancer risk and im-
pact of disease-modifying treatments in patients with multiple
sclerosis. Mult Scler 2008;14:399–405.
12. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland
H. Multiple sclerosis and cancer in Norway. A retrospective co-
hort study. Acta Neurol Scand 1996;93:411–15.
13. Moller H, Kneller RW, Boice JD Jr, Olsen JH. Cancer incidence
following hospitalization for multiple sclerosis in Denmark.
Acta Neurol Scand 1991;84:214–20.
14. Palo J, Duchesne J, Wikstrom J. Malignant diseases among pa-
tients with multiple sclerosis. J Neurol 1977;216:217–22.
15. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in
patients attending multiple sclerosis clinics. Neurology 1991;41:
1193–96.
16. Vineis P, Crosignani P, Vigano C et al. Lymphomas and multiple
sclerosis in a multicenter case-control study. Epidemiology
2001;12:134–35.
17. Hjalgrim H, Rasmussen S, Rostgaard K et al. Familial clustering
of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst
2004;96:780–84.
18. Landgren O, Kerstann KF, Gridley G et al. Re: Familial cluster-
ing of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer
Inst 2005;97:543–44.
19. Levin LI, Munger KL, Rubertone MV et al. Temporal relation-
ship between elevation of Epstein-Barr virus antibody titers and
initial onset of neurological symptoms in multiple sclerosis.
JAMA 2005;293:2496–500.
20. Hjalgrim H, Askling J, Rostgaard K et al. Characteristics of
Hodgkin’s lymphoma after infectious mononucleosis. N Engl J
Med 2003;349:1324–32.
21. Levin LI, Chang ET, Ambinder RF et al. Atypical prediagnosis
Epstein-Barr virus serology restricted to EBV-positive Hodgkin
lymphoma. Blood 2012;120:3750–55.
22. Nielsen TR, Rostgaard K, Nielsen NM et al. Multiple sclerosis
after infectious mononucleosis. Arch Neurol 2007;64:72–75.
23. Monnereau A, Glaser SL, Schupp CW et al. Exposure to UV radi-
ation and risk of Hodgkin lymphoma: a pooled analysis. Blood
2013;122:3492–99.
24. Beretich BD, Beretich TM. Explaining multiple sclerosis preva-
lence by ultraviolet exposure: a geospatial analysis. Mult Scler
2009;15:891–98.
25. Enciso-Mora V, Broderick P, Ma Y et al. A genome-wide associ-
ation study of Hodgkin’s lymphoma identifies new susceptibility
loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet
2010;42:1126–30.
26. Cozen W, Li D, Best T et al. A genome-wide meta-analysis of
nodular sclerosing Hodgkin. Blood 2012; 119:469–75.
27. Urayama KY, Jarrett RF, Hjalgrim H et al. Genome-wide associ-
ation study of classical Hodgkin lymphoma and Epstein-Barr virus
status-defined subgroups. J Natl Cancer Inst 2012;104:240–53.
28. Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a pri-
mary role for cell-mediated immune mechanisms in multiple
sclerosis. Nature 2011;476:214–19.
29. Isobe N, Gourraud PA, Harbo HF et al. Genetic risk variants in
African Americans with multiple sclerosis. Neurology 2013 July
16;81(3):219–27.
30. Niens M, Jarrett RF, Hepkema B et al. HLA-A*02 is associated
with a reduced risk and HLA-A*01 with an increased risk of
developing EBVþ Hodgkin lymphoma. Blood
2007;11:3310–15.
31. Hjalgrim H, Rostgaard K, Johnson PC et al. HLA-A alleles and
infectious mononucleosis suggest a critical role for cytotoxic T
cell response in EBV-related Hodgkin lymphoma. Proc Natl
Acad Sci U S A 2010;107:6400–05.
32. Baranzini SE, Khankhanian P, Patsopoulos NA et al. Network-
based multiple sclerosis pathway analysis with GWAS data from
15,000 cases and 30,000 controls. Am J Hum Genet 2013;92:
854–65
33. Best T, Li D, Skol AD et al. Variants at 6q21 implicate PRDM1
in the etiology of therapy-induced second malignancies after
Hodgkin’s lymphoma. Nat Med 2011;17:941–43.
34. Cozen W, Timofeeva MN, Li D et al. A meta-analysis of
Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel suscepti-
bility locus. Nat Commun 2014;5:3856.
35. Goris A, van SJ, Diekstra F et al. No evidence for shared gen-
etic basis of common variants in multiple sclerosis and
amyotrophic lateral sclerosis. Hum Mol Genet
2014;23:1916–22.
36. Gourraud PA, McElroy JP, Caillier SJ et al. Aggregation of mul-
tiple sclerosis genetic risk variants in multiple and single case
families. Ann Neurol 2011;69:65–74.
37. Isobe N, Damotte V, Lo R et al. Genetic burden in multiple scler-
osis families. Genes Immun 2013;14:434–40.
38. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL.
The human disease network. Proc Natl Acad Sci U S A
2007;104:8685–90.
39. Wang K, Ng SK, McLachlan GJ. Clustering of time-course gene
expression profiles using normal mixture models with autore-
gressive random effects. BMC Bioinformatics 2012;13:300.
40. Himmelstein D, Khankhanian P, Baranzini SE. A human disease
network from GWAS loci. Zenodo 2015.
41. Himmelstein D. Extracting disease-gene associations from the
GWAS Catalog. ThinkLab 2015.
42. Welter D, MacArthur J, Morales J et al. The NHGRI GWAS
Catalog, a curated resource of SNP-trait associations. Nucleic
Acids Res 2014;42(Database issue):D1001–D1006.
43. Plun-Favreau H, Lewis PA, Hardy J, Martins LM, Wood NW.
Cancer and neurodegeneration: between the devil and the deep
blue sea. PLoS Genet 2010;6:e1001257.
44. Huang X, Kushekhar K, Nolte I et al. HLA associations in clas-
sical Hodgkin lymphoma: EBV status matters. PLoS One
2012;7:e39986.
45. Niens M, van den Berg A, Diepstra A et al. The human leukocyte
antigen class I region is associated with EBV-positive Hodgkin’s
lymphoma: HLA-A and HLA complex group 9 are putative can-
didate genes. Cancer Epidemiol Biomarkers Prev
2006;15:2280–84.
46. Johnson PC, McAulay KA, Montgomery D et al. Modeling HLA
associations with EBV-positive and -negative Hodgkin lymph-
oma suggests distinct mechanisms in disease pathogenesis. Int J
Cancer 2015;137:1066–75.
47. Beecham AH, Patsopoulos NA, Xifara DK et al. Analysis of im-
mune-related loci identifies 48 new susceptibility variants for
multiple sclerosis. Nat Genet 2013;45:1353–60.
12 International Journal of Epidemiology, 2016, Vol. 0, No. 0
 at Periodicals D
ept on M
arch 21, 2016
http://ije.oxfordjournals.org/
D
ow
nloaded from
 
48. Lang HL, Jacobsen H, Ikemizu S et al. A functional and struc-
tural basis for TCR cross-reactivity in multiple sclerosis. Nat
Immunol 2002;3:940–43.
49. Kuppers R. The biology of Hodgkin’s lymphoma. Nat Rev
Cancer 2009;9:15–27.
50. Jarrett RF. Viruses and Hodgkin’s lymphoma. Ann Oncol
2002;13(Suppl 1):23–29.
51. Fallah M, Liu X, Ji J, Forsti A, Sundquist K, Hemminki K.
Hodgkin lymphoma after autoimmune diseases by age at
diagnosis and histological subtype. Ann Oncol
2014;25:1397–404.
52. Landgren O, Caporaso NE. New aspects in descriptive, etio-
logic, and molecular epidemiology of Hodgkin’s lymphoma.
Hematol Oncol Clin North Am 2007;21:825–40.
53. Landgren O, Engels EA, Pfeiffer RM et al. Autoimmunity and sus-
ceptibility to Hodgkin lymphoma: a population-based case-con-
trol study in Scandinavia. J Natl Cancer Inst 2006;98:1321–30.
54. World Health Organization. Classification of Tumours of
Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008.
55. Landgren O, Engels EA, Caporaso NE et al. Patterns of auto-
immunity and subsequent chronic lymphocytic leukemia in
Nordic countries. Blood 2006;108:292–96.
56. Baecklund E, Smedby KE, Sutton LA, Askling J, Rosenquist R.
Lymphoma development in patients with autoimmune and in-
flammatory disorder - what are the driving forces? Semin Cancer
Biol 2014;24:61–70.
International Journal of Epidemiology, 2016, Vol. 0, No. 0 13
 at Periodicals D
ept on M
arch 21, 2016
http://ije.oxfordjournals.org/
D
ow
nloaded from
 
